Jakub Hlávka, PhD

Director of Health Economics, Policy and Innovation Institute (HEPII) (Masaryk University, Brno, Czech Republic)

Clinical Associate Professor (Adjunct) of Population and Public Health Sciences (University of Southern California, Los Angeles, CA)

Jakub Hlávka, Ph.D. is the Head of the Health Economics, Policy and Innovation Institute (HEPII) at Masaryk University, Brno, Czech Republic, Clinical Associate Professor (Adjunct) of Population and Public Health Sciences at the University of Southern California (USC) and a Non-Resident Fellow at the Leonard D. Schaeffer Center for Health Policy & Economics, also at USC. 

Dr Hlávka's interests include Alzheimer's disease and the economics of aging, innovative payment for emerging therapies, incl. cell and gene therapies in oncology, neurology and cardiovascular disease, health system reform and the study of inequality, and resilience and preparedness in both healthcare and national security.

Between 2019 and 2023, he served as a project manager of a $2.3-million NIH grant "Ensuring Access To Novel Alzheimer’s and Dementia Treatments", which resulted in more than two dozen peer-reviewed publications in leading health economics and policy journals. His research on the COVID-19 pandemic was funded by the CDC and DHS. 

He has also served as a research consultant for the National Academies of Sciences, Engineering, and Medicine (NASEM) and its Committee on Improving Representation of Women and Underrepresented Minorities in Clinical Trials and Research. He is a member of the International Pharmaco-Economic Collaboration on Alzheimer’s Disease (IPECAD). In volunteer capacity, he has worked with a non-profit medical center in a low-income neighborhood of Dandora in Nairobi, Kenya. 

He previously worked at the RAND Corporation on issues related to national security, defense planning, and access to health care, at Genentech on R&D pipeline and portfolio planning, consulted for the Tufts Medical Center on outcome measurement in oncology, at the Fraunhofer Society, Germany on intellectual property regulation, at RAND Europe in Cambridge on emerging technologies and defense cooperation, with the Czech Government on fight against corruption, and the Czech Ministry of Finance on capital markets regulation. 

Dr. Hlávka has been named a Young Leader by Aspen Institute Central Europe, a Leader of Tomorrow by the St. Gallen Symposium, and a Global Shaper by the World Economic Forum. 

Dr. Hlávka holds a PhD from the Pardee RAND Graduate School, a master’s degree from Georgetown University, Edmund A. Walsh School of Foreign Service, and an undergraduate degree from the University of Economics in Prague. 

Learn more about my research in applied economics, health and international affairs.

Learn more about my teaching at the University of Southern California.

A little about my classical music and endurance sport interests!

Selected impact of my work on public discourse and economic policy.

A collection of interesting or insightful readings.

LATEST PUBLICATIONS FOR DOWNLOAD 

Walmsley, T., Rose, A., John, R., Wei, D., Hlávka, J. P., Machado, J., & Byrd, K. (2022). Macroeconomic consequences of the COVID-19 pandemic. Economic Modelling, 106147. Full-text PDF. Paper URL.

Handels, R. L., Green, C., Gustavsson, A., Herring, W. L., Winblad, B., Wimo, A., Hlávka, J. P. ... & IPECAD modeling workshop 2020 participants (2022). Cost‐effectiveness models for Alzheimer's disease and related dementias: IPECAD modeling workshop cross‐comparison challenge. Alzheimer's & Dementia. Full-text PDF. Paper URL.

Hlávka, J. P., Tysinger, B., Jeffrey, C. Y., & Lakdawalla, D. N. (2022). Access to Disease-Modifying Alzheimer’s Therapies: Addressing Possible Challenges Using Innovative Payment Models. Value in Health. Paper Full-Text 

Hlávka, J. P., Lavelle, T. A., Neumann, P. J., & Lin, P. J. (2022). Addressing Challenges to Alternative Payment Models for New Alzheimer’s Disease Therapies for US Commercial Payers. PharmacoEconomics, 1-6. Paper Full-Text

Yu, J. C., Hlávka, J. P., Joe, E., Richmond, F. J., & Lakdawalla, D. N. (2022). Impact of non‐binding FDA guidances on primary endpoint selection in Alzheimer's disease trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 8(1), e12280. Paper Full-Text

Hlávka, J. P., Kinoshita, A. T., Fang, S., & Hunt, A. (2021). Clinical Outcome Measure Crosswalks in Alzheimer’s Disease: A Systematic Review. Journal of Alzheimer's Disease, 83(2), 591-608. Full-text PDF. Paper URL.

Hlávka, J. P., Jeffrey C. Yu, Dana P. Goldman & Darius N. Lakdawalla. (March 2021). The Economics of Alternative Payment Models for Pharmaceuticals (2021), The European Journal of Health Economics. Full-text PDF. Paper URL

Shekelle, P.G., Goldman D.P., Hlávka J.P., ... (August 2020). Prospects for Future Advances in Alzheimer’s Disease. USC Schaeffer Center White Paper. Full-Text PDF. Paper URL.

Hlávka, J. P. (2020). Security, privacy, and information-sharing aspects of healthcare artificial intelligence. Artificial Intelligence in Healthcare. Academic Press (Elsevier), pp.235-270. Full-Text PDF. Book URL. Chapter link.

Hlávka, J. P., Mattke, S., & Wilks, A. (2020). The Potential Benefits of Deferred Payment for a Hypothetical Gene Therapy for Congestive Heart Failure: A Cost-Consequence Analysis. Applied Health Economics and Health Policy, 1-9. Full-Text PDF. Paper URL.

Mulligan, K., Lakdawalla, D., Neumann, P. J., Wilensky, G. R., Goldman, D. P., Katz, R. J., Hlávka, J.P. ... & Ryan, M. (2020). Health Technology Assessment For The US Healthcare System: A White Paper From the USC Schaeffer Center ‒ Aspen Institute Advisory Panel on Health Technology Assessment in the US. USC Schaeffer Center and Aspen Institute. Full-Text PDF. Paper URL.

Hlávka, J. P., Lin, P. J., & Neumann, P. J. (2019). Outcome Measures for Oncology Alternative Payment Models: Practical Considerations and Recommendations. The American Journal of Managed Care, 25(12), e403-e409. Full-Text PDF. Paper URL.

Lam, J., Hlávka, J. P., & Mattke, S. (2019). The potential emergence of disease-modifying treatments for Alzheimer disease: the role of primary care in managing the patient journey. The Journal of the American Board of Family Medicine, 32(6), 931-940. Full-Text PDF. Paper URL.

Hlavka, J. P., Soeren Mattke, and Jodi L. Liu, Assessing the Preparedness of the Health Care System Infrastructure in Six European Countries for an Alzheimer's Treatment, Santa Monica, Calif.: RAND Corporation, RR-2503-BIOG, 2018.  Full-Text PDF. Paper URL.

Click for other articles

UPDATES